Cystic fibrosis

Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, CSL, Safety, Research, DNA, Ornithine transcarbamylase deficiency, Therapy, Cystic fibrosis, Technology transfer, Liver, Clinical trial, Database, COVID-19, Patient, FDA, PMDA, Vaccine, ARCT, Messenger, Valencia CF Foundation, Arcturus Therapeutics, Conference, RNA, Ferret, Infection, Ivacaftor, CFTR, OTC, Government, HIV disease progression rates, Transfection, Travel, COVID, Pharmaceutical industry, Cryptocurrency, Arcturus

“We had considerable progress this quarter expanding our next generation STARR® vaccine platform,” said Joseph Payne, President & CEO of Arcturus Therapeutics.

Key Points: 
  • “We had considerable progress this quarter expanding our next generation STARR® vaccine platform,” said Joseph Payne, President & CEO of Arcturus Therapeutics.
  • ARCALIS Inc., the Company’s manufacturing joint venture in Japan to support the production of mRNA vaccines and therapeutics, continues to make operational progress while also obtaining financial support from the Japanese government.
  • Arcturus achieved a milestone for $35 million and anticipates receipt from CSL in November 2023.
  • Arcturus expects the final database lock to occur in the fourth quarter of 2023.

Artificial Organs Global Market Report 2023: A Potential $17.7 Billion Opportunity by 2027 - Benefits of Artificial Organs Over Traditional Transplants Drive Market Expansion - ResearchAndMarkets.com

Retrieved on: 
Monday, November 13, 2023
Hospitals, Health, Surgery, Medical Supplies, Kidney disease, COPD, Artificial organ, Prevalence, Cardiomyopathy, Investment, Liver cancer, Pelvic floor dysfunction, End organ damage, Idiopathic pulmonary fibrosis, Pulmonary hypertension, Viral, Inflammation, Chronic obstructive pulmonary disease, Blood, Organ transplantation, Ageing, Infection, Myocarditis, Growth, Cystic fibrosis, Moyamoya disease, Organic, Accident, Sonova, LivaNova, Smoking, Blood pressure, Aquaculture, Dentistry

This report is a comprehensive study of the global artificial organs market.

Key Points: 
  • This report is a comprehensive study of the global artificial organs market.
  • It describes the artificial organs market, segmented by product type and region.
  • Based on product type, the market is segmented into artificial hearts, artificial kidneys, artificial lungs, artificial pancreases, and cochlear implants.
  • Emerge more prepared and stay at the forefront of the global artificial organs market.

Esiason and Sims Headline Freed-Hardeman's 59th Annual Benefit Dinner, Topping $1.4 Million

Retrieved on: 
Friday, December 15, 2023
Research, Ryman Auditorium, Student, Multimedia, Boomer Esiason, NFL, FHU, Friends, University, Freed–Hardeman University, Ryman, Morehead State University, Education, UMSL Student Government Association, Commons, Cystic fibrosis, Mobile phone, Nightclub, Management, Trustee

HENDERSON, Tenn., Dec. 15, 2023 /PRNewswire-PRWeb/ -- The 59th Annual Freed-Hardeman University Benefit Dinner welcomed two NFL greats, turned commentators, Boomer Esiason and Phil Sims, as featured speakers for a very special evening Friday, Dec. 1. This year's event, which also included Christmas festivities, a dinner and student entertainment, raised $1,468,436 for student scholarships.

Key Points: 
  • Boomer Esiason and Phil Sims headlined the 59th Annual Freed-Hardeman University Benefit Dinner, helping to raise $1,468,436 for student scholarships.
  • HENDERSON, Tenn., Dec. 15, 2023 /PRNewswire-PRWeb/ -- The 59th Annual Freed-Hardeman University Benefit Dinner welcomed two NFL greats, turned commentators, Boomer Esiason and Phil Sims, as featured speakers for a very special evening Friday, Dec. 1.
  • The newly formed FHU Legacy Jazz Ensemble, led by Dr. Michael Yopp, entertained the crowd before the evening's headline speakers.
  • During a talk-show-style interview with Shannon, Esiason and Sims addressed an "auditorium full of givers" to discuss their own personal lives, backgrounds and influences.

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

Chronic Rhinosinusitis with Nasal Polyps Market to Witness Upsurge in Growth at a CAGR of 10.03% During the Study Period (2019-2032), Examines DelveInsight

Retrieved on: 
Thursday, December 7, 2023
Pressure, Nonsteroidal anti-inflammatory drug, Polyp (medicine), AstraZeneca, Inflammation, Face, Budesonide, Omalizumab, CRS, Eosinophilic granulomatosis with polyangiitis, Disease, Network congestion, PROPEL, Sleep apnea, Patient, Snoring, EU4, Sinusitis, Polyp, Allergic rhinitis, Fluticasone, Endoscopy, Smell, Nasal administration, Aspirin, Ibuprofen, Diagnosis, Cystic fibrosis, Tezepelumab, Risk, Growth, Glucocorticoid, Recurrence, Rhinorrhea, Mometasone, Physician, Asthma, LAS, Taste, GSK plc, Paranasal sinuses, Amgen, Pharmaceutical industry, Nursing

LAS VEGAS, Dec. 7, 2023 /PRNewswire/ -- DelveInsight's Chronic Rhinosinusitis with Nasal Polyps Market Insights report includes a comprehensive understanding of current treatment practices, chronic rhinosinusitis with nasal polyps emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

Key Points: 
  • Leading chronic rhinosinusitis with nasal polyps companies such as AstraZeneca, Amgen, GlaxoSmithKline, Keymed Biosciences, Biohaven Pharmaceuticals, and others are developing novel chronic rhinosinusitis with nasal polyps drugs that can be available in the chronic rhinosinusitis with nasal polyps market in the coming years.
  • The promising chronic rhinosinusitis with nasal polyps therapies in the pipeline include FASENRA (benralizumab), TEZSPIRE (tezepelumab), Depemokimab/GSK3511294, CM310, NURTEC (rimegepant), and others.
  • Chronic rhinosinusitis is an inflammatory disease of the paranasal sinuses and nasal tube lining that lasts for more than 4 to 12 weeks.
  • To know more about chronic rhinosinusitis with nasal polyps treatment guidelines, visit @ Chronic Rhinosinusitis with Nasal Polyps Management

The Inner Circle Acknowledges, Dr. Eugene H. Lewis III as a Life Achiever 2023 for his contributions to the field of Pathology

Retrieved on: 
Monday, December 4, 2023
Inner circle, Associate, Pernicious anemia, Medical director, Medical Center, Memorial, Gastritis, Medicine, College, Life, Student, Patient, Multimedia, Hartford Hospital, American Board of Pathology, Mentorship, University, Cancer, Doctor of Philosophy, Quinnipiac University, Family, Physician, St. Vincent's HealthCare, Education, Cystic fibrosis, Medical device, Pathology

FAIRFIELD, Conn., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Eugene H. Lewis III is acknowledged as a Life Achiever 2023 for his contributions to the field of Pathology.

Key Points: 
  • FAIRFIELD, Conn., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Eugene H. Lewis III is acknowledged as a Life Achiever 2023 for his contributions to the field of Pathology.
  • He completed an Anatomic and Clinical Pathology residency at Hartford Hospital from 2000 – 2004, and was Chief Resident from 2003-2004.
  • He became board certified in Clinical and Anatomic Pathology through the American Board of Pathology.
  • With more than 16 years in the field, Dr. Lewis currently practices in Bridgeport, Connecticut as a Managing Member of Fairfield County Pathology Consultants LLC.

Make-A-Wish kids are wishing it forward this holiday season through a motivational hotline

Retrieved on: 
Monday, December 4, 2023
Olive, Holiday, Black Bear Diner, Southwest Airlines, Hope, Subaru of America, Annabel, Love, JTV, Snow, The Walt Disney Company, Medicine, Music, JetBlue, Friends, Vegas Golden Knights, Cancer, Fernie, Family, Quality of life, Jasper, Holin, Cystic fibrosis, Nightclub, Sports equipment, Snappy, United Airlines, Fanaticism

PHOENIX, Dec. 4, 2023 /PRNewswire/ -- Make-A-Wish wants to spark hope this holiday season with the debut of The Holiday Wish Line, a telephone hotline with messages recorded by wish kids designed to give callers a moment of joy as they navigate the holiday season. From Dec. 4 through Dec. 31, the hotline will give callers a break from everyday stress with messages to inspire togetherness and maintain the festive spirit.  

Key Points: 
  • PHOENIX, Dec. 4, 2023 /PRNewswire/ -- Make-A-Wish wants to spark hope this holiday season with the debut of The Holiday Wish Line, a telephone hotline with messages recorded by wish kids designed to give callers a moment of joy as they navigate the holiday season.
  • The holidays are often associated with joy and celebration, but they can also bring about a range of stress.
  • The Holiday Wish Line allows anyone, at any time, to receive a dose of hope and joy from our wish kids."
  • To learn more about the voices of the hotline and how you can help grant more wishes this giving season, visit wish.org/wishline.

J.P. Morgan Life Sciences Private Capital Partners with Blue Horizon Advisors to Fuel Early Stage Biotech and Innovative Drug Development in Abu Dhabi

Retrieved on: 
Thursday, November 16, 2023
Organization, DSM-IV codes, Lysosomal storage disease, Cleveland Clinic Abu Dhabi, Ecosystem, Obesity, Blue Horizon, Anti-transglutaminase antibodies, Summit, Growth, Hearing, Diabetes, Cystic fibrosis, Cryptocurrency

The two-day Summit will take place in conjunction with the Abu Dhabi Global Healthcare Week on May 14th – 15th, 2024.

Key Points: 
  • The two-day Summit will take place in conjunction with the Abu Dhabi Global Healthcare Week on May 14th – 15th, 2024.
  • J.P. Morgan Life Sciences Private Capital and Blue Horizon Advisors are collaborating with Lyfebulb, an innovation accelerator that sources the most impactful solutions addressing true patient needs, to conduct the event.
  • "We are thrilled to be collaborating with Blue Horizon to really shine the light on the opportunities for emerging growth biopharma companies in Abu Dhabi," stated Dr. Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital.
  • "We are excited to partner with J.P. Morgan Life Sciences Private Capital to conduct this innovation summit in Abu Dhabi," said Nabil Kobeissi, Chief Executive Officer, Blue Horizon Advisors.

Rett Syndrome Research Trust Launches the Rett Syndrome Global Registry: A Pioneering Parent-Reported Platform Designed to Expedite the Development of Genetic Medicines

Retrieved on: 
Friday, November 10, 2023
Consensus, Neurogenic claudication, Human, Rett, Registry, Consensus decision-making, Rett syndrome, Policy, CARE, Therapy, Cystic fibrosis, Baylor University, Clinical trial, Database, FDA, Baylor College of Medicine, RSRT, SHARE, FARA, Parent, WEAR, Inclusive, Vanderbilt University, Roger Hawkins (drummer), FAST, Code, Doctor of Philosophy, Patient, Quality of life, Knowledge, Cystic Fibrosis Foundation, Drug development, Pharmaceutical industry, Medical device, Research, Matrix

TRUMBULL, Conn., Nov. 9, 2023 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is excited to announce the launch of the Rett Syndrome Global Registry, a fully-remote platform for parents to share their knowledge and experiences caring for loved ones with Rett syndrome. Inclusivity is a vital component of the Rett Global Registry. It is accessible to families regardless of geographic location, access to medical facilities, or socioeconomic status. Designed to advance the development of genetic medicines, the Rett Global Registry adheres to FDA guidance documents and complies with regulatory requirements. Biopharmaceutical companies pursuing therapeutic programs for Rett are urgently waiting to analyze data collected from the Rett Global Registry. Parents of children and adults with Rett syndrome are encouraged to register as soon as possible.

Key Points: 
  • Designed to advance the development of genetic medicines, the Rett Global Registry adheres to FDA guidance documents and complies with regulatory requirements.
  • Biopharmaceutical companies pursuing therapeutic programs for Rett are urgently waiting to analyze data collected from the Rett Global Registry.
  • TRUMBULL, Conn., Nov. 9, 2023 /PRNewswire-PRWeb/ -- The Rett Syndrome Research Trust (RSRT) is excited to announce the launch of the Rett Syndrome Global Registry, a fully-remote platform for parents to share their knowledge and experiences caring for loved ones with Rett syndrome.
  • Designed to advance the development of genetic medicines, the Rett Global Registry adheres to FDA guidance documents and complies with regulatory requirements.

NASP Applauds the Senate Finance Committee for Taking Additional Steps to Address Anticompetitive PBM Practices

Retrieved on: 
Wednesday, November 8, 2023
National Association, Insurance, DIR, NASP, Haemophilia, Rare, Committee, Legislation, Meat extenders, Acquisition, Accreditation, Rheumatoid arthritis, Health, Maintenance, Administration, United States Senate Finance Subcommittee on Health Care, Medicare Part D, Growth, Organ transplantation, Pharmacy, Cystic fibrosis, Specialty pharmacy, Multiple sclerosis, House, Cancer, Patient, Senate, Hospital, Medicare, Medicaid

Washington, DC, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) thanks the Senate Finance Committee for its bipartisan efforts to address anticompetitive practices that ultimately harm beneficiary access to the specialty pharmacy of their choice.

Key Points: 
  • Washington, DC, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The National Association of Specialty Pharmacy (NASP) thanks the Senate Finance Committee for its bipartisan efforts to address anticompetitive practices that ultimately harm beneficiary access to the specialty pharmacy of their choice.
  • Today’s legislation includes efforts to strengthen and enforce the long-standing federal Any Willing Pharmacy law, an NASP advocacy priority.
  • For these beneficiaries, their pharmacies meet the patients where they are in their local communities, but typically operate from a centralized location.
  • Specialty pharmacies are accredited by an independent, third party nationally recognized accreditation organization ensuring consistent quality of extensive drug management and clinical patient care services.